Publications in collaboration with researchers from Monash University (13)

2024

  1. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 6, pp. 837-847

2021

  1. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600

2020

  1. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

    ACR Open Rheumatology, Vol. 2, Núm. 8, pp. 459-470

2015

  1. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

    Journal of Rheumatology, Vol. 42, Núm. 3, pp. 479-488

2014

  1. Dietary supplements for chronic gout

    Cochrane Database of Systematic Reviews, Vol. 2014, Núm. 10

  2. Interleukin-1 inhibitors for acute gout

    Cochrane Database of Systematic Reviews, Vol. 2014, Núm. 9

  3. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 2, pp. 328-335

  4. The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors

    Journal of Rheumatology, Vol. 41, Núm. SUPPL. 92, pp. 15-25

  5. The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 7, pp. 1316-1322

  6. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196